We have developed a protocol for the generation of genome-wide maps (meiomaps) of recombination and chromosome segregation for the three products of human female meiosis: the first and second polar bodies (pB1 and pB2) and the corresponding oocyte. pB1 is biopsied and the oocyte is artificially activated by exposure to calcium ionophore, after which pB2 is biopsied and collected with the corresponding oocyte. the whole genomes of the polar bodies and oocytes are amplified by multiple displacement amplification and, together with maternal genomic Dna, genotyped for ~300,000 single-nucleotide polymorphisms (snps) genome-wide by microarray. Informative maternal heterozygous snps are phased using a haploid pB2 or oocyte as a reference. a simple algorithm is then used to identify the maternal haplotypes for each chromosome, in all of the products of meiosis for each oocyte. this allows mapping of crossovers and analysis of chromosome segregation patterns. the protocol takes a minimum of 3-5 d and requires a clinical embryologist with micromanipulation experience and a molecular biologist with basic bioinformatic skills. It has several advantages over previous methods; importantly, the use of artificial oocyte activation avoids the creation of embryos for research purposes. In addition, compared with next-generation sequencing, targeted snp genotyping is cost-effective and it simplifies the bioinformatic analysis, as only one haploid reference sample is required to establish phase for maternal haplotyping. Finally, meiomapping is more informative than copy-number analysis alone for analysis of chromosome segregation patterns. using this protocol, we have provided new insights that may lead to improvements in assisted reproduction for the treatment of infertility.
IntroDuctIon
Chromosome segregation errors in human female meiosis are the principal cause of embryo aneuploidy leading to pregnancy loss, abnormal pregnancies and live births affected by chromosomal disorders 1 . The causes of these errors are not completely understood; however, they increase exponentially with maternal age over 35 years and are associated with reduced and/or altered patterns of genetic recombination 2 . The evidence for this has been based largely on population studies and analysis of genetic markers in trisomic pregnancies and live births 2 . Furthermore, analysis of markers that are close to the centromere in common trisomiesfor example, trisomy 21, which causes Down syndrome-has demonstrated the presence of both maternal homologs in most cases. Classically, therefore, most trisomies were thought to arise by nondisjunction of the bivalent chromosomes in the first meiotic division (meiosis I) of oogenesis.
The use of in vitro fertilization (IVF) for the treatment of infertility opened up the possibility of studying these processes directly in human gametes and early preimplantation embryos. Early pioneering studies by Angell et al. 3 , in which human oocytes at various stages were karyotyped, indicated that, rather than whole-chromosome nondisjunction, premature separation of sister chromatids at meiosis I was the major mechanism causing segregation errors. However, karyotyping oocytes and embryo cells is technically challenging, and identification of chromosomes by banding patterns is generally not possible. More recently, the development of methods for whole-genome amplification from single or small numbers of cells biopsied from preimplantation embryos and array-based comparative genomic hybridization (array CGH) has allowed chromosome copy-number analysis for all 23 pairs of chromosomes. Copy-number analysis by array CGH of all three products of female meiosis-PB1, PB2 and the corresponding fertilized oocyte-demonstrated a high incidence of aneuploidy in the oocytes of women of advanced maternal age 4 . It also confirmed that the predominant mechanism causing segregation errors in meiosis I for all affected chromosomes is premature separation of sister chromatids, with only a small minority showing whole-chromosome nondisjunction.
Whole-genome amplification at the single-cell level also allows the use of other genomics methods, including SNP microarrays and next-generation sequencing (NGS). Genome-wide SNP genotyping of both parents and a close relative of known disease status allows informative parental SNPs to be phased and compared with the genotype of embryo biopsy samples as a universal linkage-based test (karyomapping) for preimplantation genetic diagnosis of single-gene defects 5, 6 . Because karyomapping maps the parental origin of each chromosome present in the embryo cell(s), meiotic trisomies, monosomies and deletions can be detected by the presence or absence of one or both parental chromosome haplotypes. Furthermore, the transitions between parental haplotypes that are distal from the centromeres provided the first high-resolution data for meiotic recombination at the single-cell level 5 .
The identification of recombination events at the chromatid level and the analysis of chromosome segregation errors in human oocytes requires maternal haplotype analysis of all three products of meiosis-i.e., PB1, PB2 and the oocyte (collectively referred to as 'oocyte-PB trios') ( Fig. 1) . Here we describe a protocol for the following: the artificial activation of donated human oocytes, which causes the resumption and completion of meiosis II and avoids the need to create fertilized embryos for research purposes; the biopsy of PB1 and PB2 before and after activation and the isolation of the activated oocyte (Fig. 2) ; whole-genome amplification and genome-wide SNP genotyping; and the use of maternal haplotype analysis using a simple algorithm based on Mendelian segregation of maternal SNP alleles (meiomapping), which is similar in principle to karyomapping, to generate genome-wide maps of recombination in oocyte-PB trios. Using this protocol, we recently demonstrated selection for maternal recombination rates, described a novel reverse segregation pattern of chromosome segregation and presented the first direct evidence for meiotic drive in human oocytes 7 .
Development of the protocol
The meiomap protocol was developed as a tool to study recombination and chromosome segregation in human female meiosis. A previous method used donated oocytes, which were fertilized by intracytoplasmic sperm microinjection (ICSI) using donated sperm, after biopsy of PB1(ref. 8) . After PB2 biopsy, the male and female pronuclei were removed by micromanipulation, and the whole genomes of the polar bodies and female pronucleus were amplified by multiple annealing and looping-based amplification cycles. Maternal haplotyping was then achieved by NGS and bioinformatic analysis of multiple triads.
To avoid the ethical issues involved in creating fertilized embryos for research purposes and the additional manipulation required to remove the pronuclei, we based our protocol on an established method for artificial activation of oocytes arrested in metaphase of the second meiotic division, or metaphase II (MII), with calcium ionophore (A23187) [9] [10] [11] [12] [13] [14] . The activated MII oocytes resume meiosis and extrude the PB2. PB2 biopsy
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Step The mature oocyte is then activated using a calcium ionophore, and the second polar body (PB2) is then biopsied (polar body 2 biopsy; Step 27) . Note the appearance of a pronucleus in the activated oocyte (black arrow). (c) Finally, the activated oocyte is isolated from the zona pellucida, ready for tubing (Steps 31 and 32). The position of the laser is shown by a small red cross within a green circle (second and third images from left in b, and first and second images from left in c). Scale bars, 15 µm. Permission to perform this experiment was obtained from the ethical review board at Genera Clinic, Italy. Our choice of method for whole-genome amplification was based on the availability of commercial PCR-based libraries, and multiple displacement amplification (MDA) methods are used routinely for chromosome copy-number analysis by array CGH or NGS, and for karyomapping by SNP genotyping. However, for SNP genotyping, the call rates are higher and the resulting resolution of the meiomap analysis is also higher with MDA. Finally, targeted sequencing of a defined set of SNPs using a microarray is cost-effective and simplifies the bioinformatic analysis, as the same loci are analyzed in the maternal DNA and oocyte-PB trios.
Furthermore, artificial activation has been used clinically in cases of ICSI failure, with live births being reported [15] [16] [17] [18] [19] . Sources of human oocytes may include cryopreserved oocytes that are no longer required for therapeutic use or, theoretically, immature oocytes at the germinal-vesicle phase or metaphase of the first meiotic division (metaphase I(MI)) matured in vitro to MII. These are widely available, as a proportion of oocytes at these stages are collected in routine IVF cycles. Irrespective of the source of oocytes, informed patient or donor consent is mandatory. To map the positions of crossovers in the oocyte-PB trios, an algorithm is used to phase heterozygous maternal SNPs distributed across each chromosome (including the nonpseudoautosomal region of the X chromosome and excluding the Y chromosome) using a haploid PB2 or activated oocyte as a reference. This results in two notional maternal haplotypes at consecutive loci across each chromosome: maternal haplotypes 1 and 2, color-coded in yellow and green, respectively (Fig. 3) . The genotypes at all of these informative loci are then examined in each of the other trio samples and compared with the reference. If the sample genotype is homozygous and identical to the reference, it is maternal haplotype 1 (yellow). If the sample genotype is homozygous for the other SNP allele, then it is maternal haplotype 2 (green). Finally, if it is heterozygous, it is color-coded in blue, or if neither haplotype is detected for that SNP it is depicted in gray (Figs. 3  and 4) . Occasionally, heterozygous SNPs call in homozygous (haploid) regions, and we refer to these as 'allele drop-in' (ADI) events that generate low-level background 'noise' in the data (e.g., Fig. 3 : SNP 13 in PB2). Please note that because the SNP genotyping software assumes that all samples are diploid, it calls haploid SNP loci in PB2 or the activated oocyte as either 'AA' or 'BB'. We therefore refer here to these calls as 'homozygous' to distinguish these loci from genuinely heterozygous calls in, for example, PB1 where two chromatid regions from both maternal homologs are present.
Theoretically, all maternal heterozygous SNPs should be informative. However, in practice, selecting heterozygous maternal SNPs, which are, as an additional requirement, genotyped as homozygous in the chosen reference, considerably improves the consistency of haplotype calling. (Please note that because of the principle of independent segregation, each chromosome in the reference has a random grandparental origin.)
When the color-coded SNPs are displayed in columns as a consecutive series for each chromosome, the transitions that occur as a result of recombination (or 'crossovers') are evident (Fig. 4) . For PB1, each recombination is marked by a transition from a heterozygous (blue) region to a homozygous region for one of the two maternal haplotypes (yellow or green) or vice versa (Fig. 5) . For PB2 and the activated oocyte, the transitions occur between the two homozygous maternal haplotypes (yellow to green or green to yellow; Fig. 5 ). At this stage, the reference sample, which for phasing purposes is assumed to have no recombination, displays only one maternal haplotype-i.e., all SNPs coded yellow. However, in most cases, the reference chromosome will in fact be recombinant. This has the effect of creating an apparent recombination in all of the other haploid samples at that position (common crossover). This is because each SNP along a chromosome is compared with the reference; where they match they are assigned the same haplotype as the reference (yellow), and where they differ they are assigned the opposing haplotype (green). A recombination in the reference therefore causes a 'switch' in haplotype at that position across all other haploid samples from that donor (Figs. 4 and 5) . Therefore, each sample has a combination of true crossovers and common crossovers. Secondary analysis is then required to identify the common crossovers, restore them to the reference sample and remove them from all of the others (Fig. 5) .
Applications of the method
This protocol is an important advance in human oocyte research within an ethical framework that facilitates a new era of investigation into various aspects of female meiosis. It does not require the creation or destruction of fertilized human embryos, and the protocol was paramount in uncovering several novel findings 7 . These include a previously unknown meiotic segregation pattern termed 'reverse segregation', in which both homologs undergo a meiosis II-like division at meiosis I and the two nonsister chromatids segregate at meiosis II (ref. 7) . This work has also shed new light on the meiotic origin of both monosomies and trisomies. It has led to direct evidence showing that lower, genome-wide recombination rates are associated with increased missegregation of chromosomes in human female meiosis, suggesting that higher recombination rates are selected for in the female germ line 7 . The studies also revealed direct evidence of meiotic drive, in which nonrecombinant chromatids are preferentially excluded from the oocyte 7 . This protocol is central for further oocyte-PB trio analysis and is being used by the Human MeioMap Project to explore human female meiosis on a broader population scale (http://www.sussex.ac.uk/lifesci/hoffmannlab/research/meiomap).
Currently, the protocol is optimized for oocytes arrested at MII. However, it could also theoretically be applied to surplus immature, germinal-vesicle-stage or MI-stage oocytes from human IVF cycles that are otherwise unused and can be matured in vitro to the metaphase stage of the second meiotic division. This would require an additional in vitro maturation step of up to 48 h of culture before starting the protocol 14 . Nevertheless, these oocytes represent a potentially large resource that, with patients' informed consent, could enable easy and ethical access to material for the study of human female meiosis. Application of this method will also provide a validation tool to assess various in vitro maturation protocols. Genome-wide mapping of female meioses can also be achieved by analyzing the SNP genotype of PB1, PB2 and fertilized embryos (embryo-PB trios). However, for embryo-PB trios, the presence of the paternal genome in the embryo samples has to be taken into account. One option is to genotype both parents and perform karyomap analysis 5 . Unlike meiomap analysis, in which all heterozygous maternal SNP loci are potentially informative, karyomapping identifies two sets of informative SNP loci for the paternal and maternal chromosomes, in which one parent is heterozygous and the other parent is homozygous. Informative SNPs are then phased-typically using a child or, with embryo-PB trios, a sibling embryo as reference-and compared with the genotype of each sample. This has the advantage that crossovers between the paternal chromosomes can be identified in the same embryos. However, the resolution is lower because two distinct sets of informative SNPs are used to define the parental haplotypes, and the number of these SNP loci is substantially reduced. Alternatively, meiomap analysis as described here can be used with a PB2 or an embryo as reference, with the additional requirement that both the reference and sample SNP genotypes are homozygous. Compared with oocyte-PB trios, this again reduces the number of informative SNP loci and the resolution, but it is still effective. For purposes of brevity, we refer to oocyte-PB trios only throughout the protocol, as in all other aspects the protocol is the same.
In theory, meiomapping or karyomapping of polar bodies alone could be used for preimplantation genetic diagnosis to identify maternal meiotic errors resulting in aneuploidy in the corresponding fertilized embryo, to diagnose the inheritance of maternal structural chromosome defects or for linkage-based detection of single-gene defects. However, neither of these protocols has been validated for clinical use, and establishing which maternal haplotype is associated with a genetic defect is still required. This would require some knowledge of familial genotypes, such as the genotype of an affected child or relative.
Comparison with other methods: advantages and limitations
Until the introduction of genome-wide sequence analysis 8 and meiomapping, studies of the relationship between recombination and meiotic chromosome segregation in humans were confined to population-based studies [20] [21] [22] [23] . Most of these analyses are limited to trisomies that are compatible with in utero development, and therefore such analyses cannot ascertain the meiotic origins of monosomies, the vast majority of which do not give rise to clinically recognized pregnancies. Furthermore, by only examining one product of meiosis, the oocyte (without the information from polar bodies), chromosome missegregation patterns and total recombination rates can only be estimated.
One major advantage of meiomapping is its power to detect global recombination rates in human oocytes. Previously, the only method of detecting recombination across all 23 homologs was through cytological analysis of Mlh1 (which marks crossovers) in fetal oocytes 24, 25 . However, this method cannot determine crossovers that may have arisen through Mlh1-independent pathways (e.g., Mus81-dependent crossovers, which account for <10% of crossovers 26 ). Meiomapping provides an additional advance over these cytological assessments in that it provides information about which of the four chromatids in a bivalent recombined at any given crossover.
The second major advantage of meiomapping is its capacity to reveal the chromosome segregation patterns that result in aneuploidy. Previously, this could only be inferred from pericentromeric SNPs in trisomic conceptions 20, 27 , which are potentially subject to interpretation errors. However, more recently, chromosome copy-number analysis of polar bodies by array CGH has enabled new insight into the prevalence of segregation errors in preimplantation embryos following IVF 4, 28, 29 . Array CGH differs from meiomapping in that it can report chromosome copy-number losses or gains in the polar bodies, which can in turn reveal any losses/gains in the fertilized oocyte, but it cannot distinguish maternal haplotypes and therefore cannot show whether homologs or sister chromatids missegregated.
To obtain results similar to those observed with our protocol, Hou et al. 8 used ICSI to induce resumption of the second meiotic division in mature (MII-arrested) human oocytes. The female pronucleus was then removed from the resulting fertilized embryos, effectively destroying them. Our oocyte activation protocol is less technically involved in that the whole oocyte is tubed rather than having to use micromanipulation to remove the pronuclei, and it does not result in the creation or destruction of human embryos for research purposes. Furthermore, our protocol results in an activation rate equal to or higher than that achieved by performing ICSI in a clinical IVF setting 30 . Hou et al. 8 used a sequencing-based approach; however, we validated our protocol using genome-wide SNP arrays. This protocol is theoretically platform independent, and it relies only on the detection of genome-wide polymorphisms. Therefore, with minor adaptation, the protocol will evolve with advances in single-cell technology, including next-generation sequencing, which has the potential to increase resolution. Although our method could be adapted to a sequencing-based approach, the efficacy and resolution depend on the read depth and level of SNP overlap across all samples (including maternal and reference genotypes). At present, the depth of sequencing required for our approach is not cost effective.
An advantage of our simple Mendelian approach as compared with other advanced bioinformatic algorithms, which identify haplotypes by analyzing multiple reference samples 8 , is that a single haploid reference (PB2 or oocyte) is sufficient to phase maternal heterozygous SNPs and detect the majority of recombination events. However, the single reference needs to be from a second oocyte-PB trio in order for all crossover events in the two trios to be identified (Table 1) . Otherwise, reciprocal crossovers between sister chromatids in the bivalent segregating to PB2 and oocyte, at precisely the same locus, will not be visible. For optimal detection of all possible crossovers, three or more oocyte-PB trios are required ( Table 1 ). The identification of common crossovers in the second and at least one other trio then allows assignment of these to the reference sample. Furthermore, availability of multiple reference samples can be helpful for resolving rare ambiguous crossovers (for example, at the extreme ends of chromosomes). It also becomes necessary to use an alternative reference if there are one or more aneuploidies or structural chromosome abnormalities in the original reference (see Troubleshooting Table 2 ).
The need to have three or more oocyte trios to detect all of the recombination events and chromosome segregation errors is an inherent limitation ( Table 1) . At present, the protocol does not allow for the separation of the two sister chromatids in PB1. Reciprocal crossovers in PB1 cannot be detected, as they exist in . In addition, not all recombination events are visible when chromosome segregation errors have taken place. For example, when an extra chromatid segregates to PB1, this will obscure the recombination events on these three chromatids so that the only detectable recombination event for that bivalent will be on the single chromatid in PB2 or the oocyte.
Meiomapping relies on efficient single-cell whole-genome amplification (WGA) and accurate SNP genotyping. Although the protocol for collection and processing of the single-cell samples is well established for clinical diagnostic use, amplification failure does occasionally occur (<5%) and is highly operator dependent. Nevertheless, if two out of three elements in an oocyte-PB trio are successfully amplified and genotyped, all of the recombinations can be identified (owing to the reciprocal nature of crossovers). In our initial study, 34 out of 40 (85%) oocytes were activated and the corresponding trios were amplified, but many samples were lost in shipment between labs 7 . Of the remaining samples, all 13 complete oocyte trios were analyzed successfully. In addition, irrespective of the method used, WGA results in a certain level of amplification errors 31 . Random failure to amplify one of the parental SNP alleles, or allele dropout, for example, is relatively common at the single-cell level, and here it results in erroneous homozygous calls in heterozygous regions (Fig. 3) . More rarely, ADI can also occur and result in erroneous genotype calls (either heterozygous or homozygous). Finally, variation of amplification across the genome at the sequence level results in a notably increased proportion of SNPs that cannot be genotyped, 'no calls' and lower overall call rates. These types of errors are particularly evident in heterozygous regions, which are typically present in PB1. Indeed, with the bead array and associated software used here, heterozygous calls are much more likely to result in no calls. Overall call rates exceeding ~60% are usually satisfactory for meiomapping purposes. However, at the lower end of this range, heterozygous regions, although easily identifiable, have poorly defined boundaries. The location of the crossover is therefore best identified from either of the haploid elements (PB2 or oocyte). Fortunately, with these, ADI is rare and no-call rates are also much lower, so that in most cases the transition from one continuous series of SNP alleles for one maternal haplotype switches to the next haplotype across adjacent informative SNPs. This is reflected in the lower resolution of recombination events in PB1 compared with PB2 or oocyte.
Further limitations include the distribution of SNP loci genotyped on the array. The coverage of the array in this protocol exceeds 90% of the genome. However, there are large gaps on the q arms of chromosomes 1 and 9, and recombination in these regions requires careful interpretation (see Troubleshooting  Table 2 ). In addition, the density of SNP markers varies across the genome and, consequently, so does the resolution of the position of recombination events.
Finally, any studies of human oocytes (or embryos) are limited by their restricted availability from clinics involved in fertility treatment and legal regulations. They must be ethically sourced with patients' informed consent, and preferably taken by someone who is not directly involved in the research.
Experimental design
Level of expertise. Access to human oocytes and embryos for research is possible only through collaboration with an IVF clinic with suitably qualified personnel and the expertise to stimulate the ovaries appropriately, collect the oocytes and so on. The protocol for meiomapping itself requires a clinical embryologist with micromanipulation experience to perform polar body biopsy and to activate and then isolate the oocytes, as well as a molecular biologist with basic bioinformatic skills. With suitable training, the clinical embryologist can collect the samples and perform the WGA. The amplified DNA can be sent to a service lab for SNP genotyping, or this can be performed in-house if SNP arrays are available. Basic bioinformatic skills and knowledge of programming, for example, using Visual Basic for Applications in Microsoft Excel, is necessary to develop the tools to analyze and display the SNP data (see example in Supplementary Data).
Genomic DNA. Genomic DNA from the oocyte donors is obtained by standard methods using commercially available kits. Sources of DNA include blood samples, buccal cells (kits can be sent in the post to the donors) and cumulus cells removed from oocytes at the time of egg collection.
Meiomapping. Informative maternal heterozygous SNP loci are identified and phased by reference to the genotype of a haploid PB2 or oocyte. This establishes two maternal haplotypes across each chromosome. The genotypes of the polar bodies and activated oocytes are then compared with the reference haplotype, and crossovers are identified by transitions between heterozygous and homozygous regions (typically in PB1) or between opposing haplotypes in PB1, PB2 or activated oocytes. Finally, common crossovers present in all samples are identified and reassigned to the reference sample. This reveals the pattern of unique crossover events in the oocyte-PB trios, which allows the chromosome segregation patterns to be interpreted. 
no. of oocyte-pB trios crossovers detected and assigned 1 All crossovers between homologous chromosomes are detected but cannot be assigned to the specific chromatid in PB2 or oocyte. Meiomapping cannot detect crossovers occurring within heterozygous regions of the chromosome remaining in PB1 2 All crossovers between homologous chromosomes detected and assigned to PB2 or oocyte in the nonreference trio Crossovers between sister chromatids in PB2 and oocyte are detected but cannot be assigned to a specific trio.
Repeating the meiomap analysis with the reference in the second trio allows assignment in both trios
≥3
All crossovers between homologous chromosomes detected and assigned to PB2 or oocyte in all trios.
Repeating the meiomap analysis with a second reference in a different trio allows complete assignment in the trio containing the orginal reference and the other trios.
Crossovers between sister chromatids detected in all trios Recombination events can be seen by comparing the samples with a haploid (PB2 or oocyte) reference. The reference needs to be from an independent oocyte-PB trio from the same donor and ideally with a high call rate (>60%) and low heterozygous call rate (~1-2%). The requirement for an independent reference sample necessitates at least two oocyte-PB trios per donor. It is desirable to have multiple samples from the same donor, which can help overcome problems associated with aneuploidy in the reference sample or common crossovers very close to other crossovers (see Table 1 and Troubleshooting Table 2 ).
Bioinformatics techniques and analysis. The SNP calls for each chromosome and each sample are imported into a Microsoft Excel spreadsheet for primary analysis (Supplementary Data). Each SNP is classified as 'AB' (both haplotypes), 'AA' or 'BB' (each grandparental haplotype). Regions of heterozygosity (both haplotypes present) are defined by the presence of blocks of AB calls. Homozygous regions are compared SNP by SNP with a reference sample; where the SNPs match those of the reference they are assigned 'haplotype 1' (yellow), and where they differ they are assigned 'haplotype 2' (green). This results in a pattern of haplotype switching or breakpoints, which represent crossovers. Any crossovers present on the reference chromatid will manifest as 'common crossovers' across all samples (Figs. 4 and 5; red boxed region) . These are removed and added to the reference as part of the secondary analysis (see Step 46). Chromosome segregation is assessed at the end after crossover mapping as part of the secondary analysis. Noncanonical segregation patterns manifest as reciprocal losses or gains of chromosomes or chromatids, or, in the case of reverse segregation, as heterozygous SNPs surrounding the centromere in PB1. Dilute 20 .94 mg of calcium ionophore in 10 ml of DMSO to make a 4 mM stock solution. Store at −20 °C for up to 3 months. Working activation culture medium Add 100 µl of calcium ionophore stock solution to 3.9 ml of Sage cleavage medium for a final 100 µM working solution. Add 10% (vol/vol) HSA. Store at 3-5 °C for up to a week. Oocyte culture medium Add 10% (vol/vol) HSA to Sage cleavage medium (without calcium ionophore). Store at 3-5 °C for up to a week. Oocyte handling medium Add 10% (vol/vol) HSA to Sage HEPES-buffered medium. Store at 3-5 °C for up to a week. EQUIPMENT SETUP Oocyte-holding dishes Make two 25-µl drops of oocyte culture medium (one for washing, one for culture) per oocyte within culture dishes (Falcon Primaria) and overlay them with mineral oil until the drops are entirely covered. Dishes should be allowed to equilibrate in an incubator set at 37 °C in 6% CO 2 and 5% O 2 for a minimum of 3 h before use and within 24 h of preparation. Activation dishes Make two 25-µl drops of working activation culture medium (one for washing, one for culture) per oocyte within culture dishes (Falcon Primaria) and overlay them with mineral oil until the drops are entirely covered. Dishes should be allowed to equilibrate in the incubator set at 37 °C in 6% CO 2 and 5% O 2 for a minimum of 3 h before use and within 24 h of preparation. Postactivation dishes This can be done using either EmbryoSlides, if you are culturing in an EmbryoScope, or ordinary culture dishes, if standard culture is used. If standard culture is used, make two 25-µl drops of oocyte culture medium (one for washing and one for culture) per oocyte within culture dishes (Falcon Primaria) and overlay them with mineral oil until the drops are entirely covered. If EmbryoScope culture is used, fill all 12 numbered wells of the EmbryoSlide with 25 µl of oocyte culture medium, ensuring that the microwell at the bottom is free of bubbles. Completely fill the wash wells (with no micro-well) with the same medium and overlay with mineral oil until the wells are entirely covered.
Both culture dishes and EmbryoSlides should be allowed to equilibrate in an incubator set at 37 °C in 6% CO 2 and 5% O 2 for a minimum of 3 h before use and within 24 h of preparation. Biopsy dishes Make two 10-µl drops of oocyte-handling medium per oocyte (one wash drop, one working drop) within biopsy dishes and overlay with mineral oil. Allow them to equilibrate on a heated stage (37 °C) for a minimum of 20 min before use; use within 1 h. 28 . Move all mature MII oocytes to an oocyte-holding dish containing oocyte culture medium (see Reagent Setup) ready for biopsy and activation.  crItIcal step It is imperative to ensure complete removal of surrounding cumulus cells before proceeding. Incomplete removal of all maternal somatic cells surrounding the oocyte could result in maternal contamination and will be apparent in the downstream SNP analysis. We recommend the removal of cumulus cells by pipetting the oocytes up and down with a 130-µm pipette in hyaluronidase solution. At this point, oocytes may be vitrified for batching purposes before the protocol is begun 33 .
First polar body biopsy • tIMInG 15-30 min
 crItIcal The activation and biopsy parts of the protocol (Steps 2-34) could feasibly be performed by a single operator. However, it is recommended that two operators work in tandem at time points at which certain activities can be performed in parallel (e.g., biopsy and tubing) to avoid delays in processing, thus preserving the sample's integrity, especially when performing the protocol on more than six oocytes at the time. The biopsy should be performed as soon as possible after polar body extrusion. See Troubleshooting table 2 for advice on polar body fragmentation. 2| At a stereo microscope workstation, use a 170-µm stripper to move the prepared oocytes from the culture dish in Step 1 to a biopsy dish (see Reagent Setup) with individually numbered 10-µl microdrops of HEPES medium + 10% HSA under Sage oil. Use the one available wash drop per oocyte to ensure that each oocyte is free from any cellular debris by gently pipetting each oocyte up and down several times before allocating it to its biopsy working drop. The number of oocytes per dish is dependent on the skill of the operator.  crItIcal step We recommend that no more than 15 min should pass between the oocytes entering the dish and being removed after biopsy (from 1 to 6 oocytes per dish).
? trouBlesHootInG 3| Place the biopsy dish containing the oocytes on the inverted microscope (with micromanipulators and laser attached) to give a clear view of the PB, and secure the oocyte by suction with the holding pipette, ensuring that the oocyte is just above the bottom of the dish (Fig. 2a) .
4|
Rotate the oocyte using the aspiration pipette until the PB is clearly in focus at 12 to 1 o'clock. If this is done correctly, the zona pellucida should also be clearly in focus (Fig. 2a) .  crItIcal step It is essential to maintain a gentle yet constantly complete seal between the holding pipette and the oocyte, as even a small break in the seal could result in a poor outcome.
5|
Once the oocyte is correctly positioned for biopsy, use a series of laser pulses to make a small aperture (no larger than the diameter of the aspiration pipette) in the zona pellucida, adjacent to the PB on the side of the aspiration pipette. Work inward from the outer surface of the zona.  crItIcal step Attention must be paid so as not to fire a laser pulse at the cytoplasm of the oocyte or PB.
6|
Insert the aspiration pipette through the opening in the zona, and position the lumen of the pipette adjacent to the PB.
7|
Use the aspirator to create a small amount of suction and slowly withdraw to remove the PB. If the PB is still attached to the oocyte, break the intercellular bond using a single laser pulse, on the lowest intensity setting, at the cell junction to release the bond.  crItIcal step Ideally, the polar body should not fully enter the biopsy pipette. The suction created should simply allow the polar body to be drawn through the breach in the zona. Complete aspiration of the polar body may result in lysis, which may not affect amplification but makes tubing unreliable. If PB1 is fragmented during biopsy, ensure that all fragments are removed for tubing. oocyte activation • tIMInG 45-50 min 8| Move the biopsy dish containing the biopsied oocytes to a stereomicroscope workstation immediately after completing biopsy of all oocytes contained within the dish.  crItIcal step Care must be taken during this step and onward so as not to exert too much pressure on the biopsied oocytes when pipetting. Slow pipetting using 170-µm stripper pipettes with gentle aspiration and expulsion is recommended.
9|
Identify both the PB and the oocyte under the stereomicroscope. Use a 170-µm stripper pipette to transfer individual oocytes, one at a time, to individually numbered drops in an activation culture dish, leaving the biopsied PB1 behind in the biopsy dish for immediate tubing.
10|
Use the available wash drops to gently wash each oocyte before allocating it to its activation culture drop.  crItIcal step Care must be taken not to disturb the biopsied polar body when removing the oocytes from the biopsy dish. Failure to do so may result in the polar body being lost.
11| Begin a 40-min timer from the time the last oocyte is transferred to the activation culture dish, and put the dish in the incubator until the 40-min time is up.  crItIcal step At this point, further PB1 biopsy can be performed according to Steps 2-11. If this is desired, a second operator should perform the tubing procedure below in parallel.
pB1 tubing • tIMInG 15-30 min  crItIcal Prepare liquid nitrogen bath in advance for PB storage. 12| Add 1 µl of PBS to the appropriate number of 0.2-ml, RNase-and DNase-free, thin-walled, flat-cap PCR tubes for the number of polar bodies, and label each tube appropriately.
13|
To avoid evaporation and contamination, close the cap on the tubes gently (loose cap).  crItIcal step Caps should be closed, but they should be easily releasable for depositing the samples. The 1 µl of PBS should remain at the bottom of the tubes. If small drops form on the sides of tubes, give the tubes a quick spin on the microcentrifuge before depositing the samples.
14| Focus on the polar body from
Step 7 with the stereomicroscope, using the mirror to create contrast for best visibility.
15|
Set the stripper pipette to 1 µl and, using a 120-µm pipette tip, prime as much as possible with PBS. Depress the plunger all the way, aspirating PBS into the pipette until the plunger is entirely released.  crItIcal step For best results, use a new stripper tip for each sample.
16|
Enter the drop with the pipette tip while gently expelling a small amount of PBS to ensure that no oil blocks the tip. No more than 0.5 µl should need to be expelled.  crItIcal step If any oil droplets are visible in the pipette tip, try to clear it by vigorous aspiration in clean PBS or replace it and restart from Step 15.
17| Place the pipette tip over and adjacent to the PB, and release the plunger entirely (PB should enter the pipette and remain there).  crItIcal step Ensure that the plunger and the pipette are not moved abruptly at this stage, as the sample could be lost.
18|
Open a preprimed and labeled PCR tube from Step 12 and hold the tube between the thumb and index finger so as to have a clear view through the tube from top to bottom.
19|
Insert the pipette containing the sample into the tube so that the tip enters the PBS.  crItIcal step Avoid touching the sides or the bottom of the tube, if possible.
20|
Expel the contents of the pipette into the tube, stopping when the 1-µl mark is reached. This should be when there is a point of more resistance when depressing the plunger.
21|
Keep the plunger depressed to this point, and re-enter the sample drop to expel the remaining PBS while observing any objects exiting the pipette. Pipette up and down once or twice with the medium in the drop to ensure that the PB is not stuck to the pipette wall. If the PB can no longer be seen in the pipette tip, tightly cap the tube. Move on to the remaining samples, repeating Steps 12-21. . This enables easy assessment of PB2 extrusion and pronuclear formation without the need to repeatedly remove oocytes from the incubator. It also allows monitoring of embryo development, if you are using embryos instead of activated oocytes. For our protocol, we specifically use the EmbryoScope system, which has its own proprietary dishes (EmbryoSlides); however, we also provide below options for proceeding without the use of a time-lapse incubator. 24| After 40 min of activation in culture (using samples from Step 9), remove the activation culture dish containing the oocytes from the incubator and move it to the stereomicroscope workstation.
25|
Follow option A for postactivation culture using an EmbryoScope time-lapse incubator, or follow option B to proceed if a time-lapse incubator is not available.  crItIcal step Ensure that extra care is taken when pipetting and that suction with the holding pipette (Steps 3-4) avoids the existing aperture in the zona pellucida (Fig. 2b) .  crItIcal step If PB2 biopsy is to be performed on more than one dish of activated oocytes (the recommended maximum is six oocytes per biopsy dish), a second operator should perform the tubing procedure below in parallel. 
30|
Once the oocyte is in position, make a large aperture in the zona pellucida using a series of laser pulses. The aperture should be between a quarter to a half of the zona around. Ablate the zona using laser pulses approximately the same diameter as the zona thickness, working in a circular manner (Fig. 2c) .
31|
Insert the aspiration pipette under the zona and gently expel medium to displace the oocyte so that it is free from the zona. Ensure that the pipette contains sufficient medium, and be careful not to blow any bubbles. Gentle manual manipulation with the aspiration pipette to move the oocyte may also be necessary to help the displacement process.
32|
While still attached to the zona, move the holding pipette to the edge of the drop and deposit the zona there, leaving the oocyte in the center of the drop. WGa and snp genotyping.
• tIMInG 1-2 d  crItIcal For further details, refer to Natesan et al. 6 . 34| Use a 10-µl Gilson pipette to bring the three PCR tubes containing each of the trio samples (from Steps 20, 28 and 33) to an end volume of 4 µl with PBS.
35|
Amplify the DNA by MDA using a kit according to the manufacturer's instructions (SureMDA, Illumina). 40| Select a reference sample (either a PB2 or an activated oocyte).  crItIcal step Note that to maximize the number of informative SNP loci, a reference sample with a high call rate and low heterozygous call rate (ADI) should be selected. The call rates should exceed 80%, although anything above 60% is acceptable, and the heterozygosity rate should be in the region of 1-2%.
36|

41|
Identify all informative maternal heterozygous SNP loci genotyped as homozygous in the reference sample (AA or BB) and defined as maternal haplotype 1 (yellow) for each chromosome (Fig. 3) .
42|
Compare sample genotypes to the reference genotype at informative maternal SNP loci for each chromosome and identify as follows: (i) homozygous for the same allele-maternal haplotype 1 (yellow); (ii) homozygous for the other allele-maternal haplotype 2 (green); (iii) heterozygous-combination of maternal haplotypes 1 and 2 (blue); or (iv) no call (gray). See Figures 3 and 4 . See Troubleshooting table 2 for explanation of anomalies caused by aneuploidy in the reference sample.
43|
Display the results of the previous step as a consecutive series of informative SNPs in vertical columns, color-coded with their base-pair position, for each chromosome. Arrange the vertical columns side by side for each sample and each chromosome (Fig. 4) .
? trouBlesHootInG 44| Use a macro that detects transitions in maternal haplotypes (based on the color of each cell) or manually annotate the positions of any crossovers indicated by the transitions described above. For manual annotation, copy and paste the informative SNPs flanking the recombination into the adjacent right-hand column, including the color-coding and base-pair position (Fig. 4, enlarged region) . See table 2 for troubleshooting advice on very closely spaced crossovers and for tagging transitions between heterozygous and homozygous haploblocks.  crItIcal step Each recombination should always be present in two out of three of the products of meiosis at the same position.
? trouBlesHootInG 45| Import the flanking SNP positions for each recombination event into a separate worksheet.
46|
Remove common crossovers from each nonreference sample and add them to the reference sample (Fig. 5) .  crItIcal step It is essential to identify and remove common crossovers from all other samples and represent them only in the reference chromatid. Note that reciprocal recombination between sister chromatids in PB2 and the activated oocyte, one of which is the reference, will not be visible in the nonreference component either and need to be added back to this component, as well as the reference ( Fig. 5 ; red-dotted boxed region).
47|
Calculate the position of all crossovers as an average of the base-pair position of the two SNPs flanking a crossover. For example, the average of two SNPs flanking the crossover shown in the enlarged box in Figure 4 is 39,416,076 (green SNP position: 39,354,517; yellow SNP position: 39,477,635), and so the crossover is inferred to have occurred at position 39,416,076.
48|
Correct the haplotype colors across each true recombination following the removal of the common crossovers.
49|
Display the pattern of crossovers in each component of each trio according to its position to generate the meiomap (Fig. 4) . See table 2 for troubleshooting advice about crossovers near centromeres on chromosomes 1 and 9.
? trouBlesHootInG 50| Use further macros within Excel or manual counting to perform secondary analysis of the numbers and positions of the crossovers. Detect various chromosome segregation errors by inferred atypical patterns of homozygous and heterozygous regions in the three components in the meiomap. Please refer to Ottolini et al. 7 for comprehensive description of the various patterns.
? trouBlesHootInG Troubleshooting advice can be found in These could be genuinely closely spaced crossovers (see below). Alternatively, they may be crossovers very close to a common crossover. In the rare event that a crossover occurs at the exact same SNP position as a common crossover, this will render the common crossover invisible in this sample If this is caused by proximity to a common crossover, this should be apparent from presence of the common crossover across all samples If a crossover occurs at the exact same position as a common crossover in the reference, this will be detectable by the common crossover being 'missing' from one sample. In this scenario, it becomes advantageous to have multiple samples from the same donor in order to expose the sample with the 'missing' common crossover In either case, the true pattern of crossovers can be confirmed by using an alternative reference for that chromosome Although crossovers are generally widely spaced (owing to crossover interference), sometimes two crossovers can occur in close proximity
It is worth setting the minimum number of consecutive SNPs that are required to define a haploblock. This is also applicable to crossovers that occur very close to telomeres. If allele drop-in rates are particularly high, you may want to increase the threshold of consecutive SNPs
Tagging SNPs flanking a transition from a heterozygous to a homozygous region
Regions of heterozygosity indicate the presence of two nonsister chromatids, typically in PB1, and tend to have variable levels of allele dropout and 'no calls' (Fig. 3) . This may make it hard to judge where to 'tag' the last SNP of the heterozygous block
The nearest available heterozygous (blue) SNP to the crossover should be tagged, along with the first available SNP of the next haplotype (yellow or green). The reciprocal transition in PB2 or the activated oocyte can be used to align the precise position of the recombination event
49
Crossovers occurring across the centromere of chromosome 1 or 9
Large regions of repetitive sequences surround the centromeres of both chromosomes 1 and 9, and are therefore absent from the SNP array
As crossovers cannot be mapped directly in these regions, be aware of haplotype switches on either side of the centromere, which would indicate a crossover somewhere in this 'blind' region and which can be arbitrarily assigned to either the p or the q arm chromatids and meiosis II nondisjunction (Fig. 6b) . Note that these noncanonical segregation events do not always result in a loss/gain in the oocyte. Structural chromosome abnormalities can also be detected in meiomaps. Frequently, these are characterized by duplications on one arm of a metacentric chromosome. For example, a region of heterozygosity may exist on the q arm of PB1 and on the p arm of PB2 or the oocyte (as shown in the example in Fig. 6c) . Structural chromosome abnormalities can also manifest as missing segments of a chromosome (Fig. 6c, bottom) . The total number of crossovers genome-wide, together with the number of chromosome segregation errors, can be counted for each oocyte-PB trio and used for subsequent data analysis. 
